Cost Management Insights: SG&A Expenses for Biogen Inc. and Corcept Therapeutics Incorporated

Biogen vs. Corcept: SG&A Expense Trends Unveiled

__timestampBiogen Inc.Corcept Therapeutics Incorporated
Wednesday, January 1, 2014223234200034916000
Thursday, January 1, 2015211310000036949000
Friday, January 1, 2016194790000045240000
Sunday, January 1, 2017193550000062416000
Monday, January 1, 2018210630000081289000
Tuesday, January 1, 20192374700000100359000
Wednesday, January 1, 20202504500000105326000
Friday, January 1, 20212674300000122356000
Saturday, January 1, 20222403600000152848000
Sunday, January 1, 20232549700000184259000
Monday, January 1, 20242403700000
Loading chart...

Unlocking the unknown

Navigating SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Biogen Inc. and Corcept Therapeutics Incorporated from 2014 to 2023. Over this period, Biogen's SG&A expenses have shown a steady increase, peaking in 2021 with a 38% rise from 2014. Meanwhile, Corcept Therapeutics has experienced a remarkable surge, with expenses growing over 400% in the same timeframe. This stark contrast highlights the differing strategies and growth trajectories of these two companies. While Biogen's expenses reflect its established market presence, Corcept's rapid increase underscores its aggressive expansion efforts. Understanding these trends provides valuable insights into the financial strategies of leading biotech firms, offering a window into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025